Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Jones

Showing results (281-290 of 363) with videos related to

Pageof 37
Sort By:
JAMA Network Open|February 19, 2025
Maternal RSVpreF and Infant Nirsevimab Immunizations Uptake During Respiratory Syncytial Virus SeasonEthan A Litman, Tina Yi Jin Hsieh, Anna M Modest, et al.
Investigational New Drugs|January 19, 2013
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancerRobert Jones, Jacqueline Vuky, Tony Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2024
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT TrialAlison Jane Birtle, Robert Jones, John Chester, et al.
Environmental Microbiome|August 2, 2023
Meeting report of the sixth annual tri-service microbiome consortium symposiumIda G Pantoja-Feliciano De Goodfellow, Richard Agans, Robyn Barbato, et al.
The Lancet Regional Health. Western Pacific|July 12, 2024
Healthcare-associated infections and antimicrobial use at a major referral hospital in Papua New Guinea: a point prevalence surveyStephanie J Curtis, Roland Barnabas, Kelly A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitorsPatrick A Oberholzer, Damien Kee, Piotr Dziunycz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder CancerThomas Powles, Robert A Huddart, Tony Elliott, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|November 30, 2018
Effect of acute hypohydration on glycemic regulation in healthy adults: a randomized crossover trialHarriet A Carroll, Iain Templeman, Yung-Chih Chen, et al.
Transplantation Direct|April 20, 2023
The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New ZealandJess Howell, Avik Majumdar, Michael Fink, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
Pageof 37

Showing results (281-290 of 363) with videos related to

Sort By:
Pageof 37
JAMA Network Open|February 19, 2025
Maternal RSVpreF and Infant Nirsevimab Immunizations Uptake During Respiratory Syncytial Virus SeasonEthan A Litman, Tina Yi Jin Hsieh, Anna M Modest, et al.
Investigational New Drugs|January 19, 2013
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancerRobert Jones, Jacqueline Vuky, Tony Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2024
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT TrialAlison Jane Birtle, Robert Jones, John Chester, et al.
Environmental Microbiome|August 2, 2023
Meeting report of the sixth annual tri-service microbiome consortium symposiumIda G Pantoja-Feliciano De Goodfellow, Richard Agans, Robyn Barbato, et al.
The Lancet Regional Health. Western Pacific|July 12, 2024
Healthcare-associated infections and antimicrobial use at a major referral hospital in Papua New Guinea: a point prevalence surveyStephanie J Curtis, Roland Barnabas, Kelly A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitorsPatrick A Oberholzer, Damien Kee, Piotr Dziunycz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder CancerThomas Powles, Robert A Huddart, Tony Elliott, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|November 30, 2018
Effect of acute hypohydration on glycemic regulation in healthy adults: a randomized crossover trialHarriet A Carroll, Iain Templeman, Yung-Chih Chen, et al.
Transplantation Direct|April 20, 2023
The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New ZealandJess Howell, Avik Majumdar, Michael Fink, et al.
The Lancet. Oncology|February 22, 2015
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trialFred Saad, Karim Fizazi, Viorel Jinga, et al.
Pageof 37